Clinical Trials Logo

Hyperlipidemias clinical trials

View clinical trials related to Hyperlipidemias.

Filter by:

NCT ID: NCT02227784 Terminated - Hyperlipidemia Clinical Trials

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

ACCENTUATE
Start date: October 2014
Phase: Phase 3
Study type: Interventional

The purpose of the ACCENTUATE study is to evaluate whether the study drug known as evacetrapib is effective in treating participants with high cholesterol and atherosclerotic cardiovascular disease (ASCVD) and/or diabetes.

NCT ID: NCT02221297 Completed - Clinical trials for Hypercholesterolemia

Lipid-lowering Effect of a Plant Stanol Ester Supplement Product

Start date: May 2014
Phase: N/A
Study type: Interventional

Purpose of the study is to determine the effect of the investigational products as consumed with a meal on serum lipids, primarily on LDL cholesterol.

NCT ID: NCT02215408 Completed - Hypertension Clinical Trials

MEDication Focused Outpatient Care for Underutilization of Secondary Prevention

MEDFOCUS
Start date: January 20, 2015
Phase: N/A
Study type: Interventional

The study tested whether a pharmacist-run cardiovascular risk service (CVRS) at the University of Iowa can increase use of national standards of care in clinics

NCT ID: NCT02203227 Not yet recruiting - Hyperlipidemia Clinical Trials

Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia

Start date: August 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate hyperlipidemia after 30 and 60 days of intervention.

NCT ID: NCT02189837 Completed - Clinical trials for Primary Hyperlipidemia and Mixed Dyslipidemia

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

FLOREY
Start date: July 8, 2014
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.

NCT ID: NCT02187757 Completed - Hyperlipidemia Clinical Trials

Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels

Prelip
Start date: November 2013
Phase: Phase 3
Study type: Interventional

Study to evaluate Efficacy and Safety of PreLipid® on subjects with higher than normal blood lipid levels

NCT ID: NCT02186483 Completed - Diabetes Clinical Trials

Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the pharmacokinetic drug interaction between Metformin and Rosuvastatin in healthy male volunteers.

NCT ID: NCT02163044 Completed - Clinical trials for Coronary Heart Disease

The Hellenic Postprandial Lipemia Study (HPLS)

HPLS
Start date: September 2014
Phase:
Study type: Observational

Coronary heart disease (CHD) is the leading cause of death worldwide. The disease is characterized by a high mortality rate (about 40%) and a course continuously altered by lifestyle, gene polymorphisms and therapeutic treatment. Fasting concentration of blood lipids and lipoproteins only partially express the complex relation between dyslipidemia and CHD. Following the indication stated nearly 40 years ago by Zilversmit, there is now accumulating evidence that postprandial lipemia plays an important role in the atherogenic process [ref Kolovou], particularly that most hours of the day are spent in the postprandial state. Furthermore, the increases in blood glucose and triglycerides (TGs) following meals stimulate oxidative stress, impair endothelial function, and rises the inflammatory factors that lead to atherosclerosis. Previous studies reported on postprandial lipemia in subjects with obesity, metabolic syndrome, diabetes mellitus, elderly, patients with CHD and others. However, currently the estimation of cardiovascular disease risk is based on fasting blood values of triglycerides (TGs) and inflammatory markers. The effect of postprandial atherogenic factors on the initiation and progression of atherosclerosis is actually not known.The Hellenic Postprandial Lipemia Study (HPLS) was designed to study the consequences of postprandial lipemia in CRP as inflammatory marker in high-risk adults. Furthermore, the HPLS study will investigate whether hypolipidemic, hypoglycemic or antihypertensive medication may lessen the exaggerated postprandial lipemia as well as the rest abnormal postprandial metabolism. Finally, the HPLS study is intending to evaluate the influence of gene polymorphisms involved in lipid and glucose metabolism on postprandial lipemia and cardiovascular outcomes.

NCT ID: NCT02153073 Completed - Hyperlipidemia Clinical Trials

Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters

Start date: May 29, 2013
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical practice

NCT ID: NCT02147041 Enrolling by invitation - Diabetes Mellitus Clinical Trials

The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides

Start date: May 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to examine the therapeutic effect of green tea extract on obese women and the correlation analysis between traditional Chinese medicine syndrome and obese related hormone peptides.